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The clinical course of polycythemia vera (PV) or essential thrombocythemia (ET) patients is frequently complicated by thrombohemorrhagic episodes, and the major goal of therapy is prevention and/or treatment of these complications. In early 2005, several groups virtually simultaneously reported the presence of a specific activating mutation (JAK2V617F) in the JH2 domain of JAK2 kinase in several myeloproliferative disorders (MPD); allelic frequency is estimated at above 90% for PV and 50% for both ET and primary myelofibrosis. 1 Although the role of JAK2V617F in the development of thrombosis in MPD patients remains to be precisely elucidated, early data in PV suggest an association between JAK2V617F allele burden determined at the time of diagnosis, and the risk of developing major thrombosis (AM Vannucchi et al., Blood 2006; 108: abstract 5). Similarly, some studies in ET have reported a higher rate of venous thromboses in JAK2V617F-positive patients as compared to those harboring wild-type JAK2.
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More recently, JAK2V617F has been detected in a significant proportion (31-59%) of patients presenting with splanchnic vein thrombosis. [3] [4] [5] In this setting, JAK2V617F represents a sensitive marker for 'latent' or 'occult' MPD (that is, MPD not identifiable Letters to the Editor on the basis of conventional clinical-hematological parameters), with a subset of patients subsequently developing clinically overt MPD.
Our aim was to determine the frequency of JAK2V617F in patients with non-splanchnic venous thromboembolism (VTE) in the absence of overt MPD. We identified 210 consecutive patients (109 women; age range ¼ 17-93 years) who underwent thrombophilia testing at our institution in early 2005, for whom archived DNA specimens were available for analysis. These patients additionally satisfied the following criteria: (i) the thrombosis involved a non-splanchnic vein and was objectively documented, and (ii) a diagnosis of MPD could be excluded after a review of the clinical data. The current study was approved by our institutional review board. All patients provided informed consent, and research was carried out according to the principles of the Declaration of Helsinki.
DNA was extracted from whole blood aliquots using the Gentra Generation Capture Plate system (Minneapolis, MN, USA) and stored in 25 ng/ml aliquots. Allele-specific (AS)-qPCR assay for JAK2V617 was performed on an ABI Prism 7000 analyzer (Applied Biosystems, Foster City, CA, USA), as described previously by Levine et al. 6 Genomic DNA from HEL cells homozygous for JAK2V617F and K562 cells homozygous for wild-type JAK2 was mixed in various proportions (0, 1, 5, 10, 15, 20, 25, 50, 75, 90, 95, 99 and 100%) to generate a standard curve for JAK2 V617 /JAK2 V617 þ JAK2 WT against DC t (C tJAK2V617F À C tJAK2WT ). All samples were measured in triplicate, and the mean DC t was used to calculate JAK2 V617 / JAK2 V617 þ JAK2 WT .
Of the 210 patients, seven (3%) presented with cerebral vein thrombosis, another seven (3%) with central retinal vein occlusion, and the remaining with lower extremity deep venous thrombosis (DVT) (n ¼ 84) (40%), pulmonary embolism (PE) (n ¼ 76) (36%), or both DVT and PE (n ¼ 36) (17%). Overall, 26 patients (13%) carried the Factor V Leiden (R506Q) mutation (25 heterozygous and 1 homozygous), and 11 patients (5%) carried the factor II (prothrombin) G20210A mutation (9 heterozygous and 2 homozygous).
Four patients (2%) carried the JAK2V617F mutation ( Table 1) . Each of these patients had a history of idiopathic recurrent VTE, in the absence of clinical or hematologic features indicating underlying MPD. One patient (case 3) carried the prothrombin G20210A mutation (Table 1 ). The median JAK2V617F allele burden (JAK2 V617 /JAK2 V617 þ JAK2 WT ) for the four patients was 5.1% (range ¼ 2.2-5.3%; Table 1 ). Patients with PV served as controls for the assay, and as expected, 114 of 124 patients (92%) tested positive for JAK2V617F.
In summary, we identified a subset of patients with nonsplanchnic VTE without overt MPD who carried the JAK2V617F allele. These patients were older (median age ¼ 80 years), and had a history of recurrent unprovoked thrombosis, particularly PE. There is scant data pertaining to JAK2V617F in this population -a recent study screened 295 patients with venous thrombosis, and identified one case with recurrent idiopathic DVT who carried JAK2V617F, although mutant allele burden was not assessed. 7 In our study, the JAK2V617F allele burden in thrombosis patients was similar to that noted in ET patients (median ¼ 6.3% in 96 ET patients; Cancer, in press). A relatively low mutant allele burden has also been reported for patients with splanchnic vein thrombosis who harbor JAK2V617F.
3 Our data suggest that JAK2V617F contributes to a hypercoagulable state, although the strength of this contribution and potential interactions with other thrombophilic factors remains to be elucidated. The issue as to whether thrombosis patients who harbor JAK2V617F represent early-phase MPD or whether they represent a forme fruste of MPD will require long-term followup. These patients are likely to benefit from long-term systemic anticoagulation although the additional benefit, if any, of cytoreductive therapy remains to be determined. /l); v, vein; % V617F, JAK2 V617 /JAK2 V617 +JAK2 WT Â 100; WBC, white blood cell count ( Â 10 9 /l).
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